Your browser doesn't support javascript.
loading
Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial.
Saida, Takahiko; Kira, Jun-Ichi; Kishida, Shuji; Yamamura, Takashi; Ohtsuka, Nobuhisa; Ling, Yan; Torii, Shinichi; Lucas, Nisha; Kuesters, Geoffrey; Steiner, Deb; Tibung, J T.
Affiliation
  • Saida T; Kansai Multiple Sclerosis Center, Kyoto, Japan. saida_takahiko@maia.eonet.ne.jp.
  • Kira JI; Department of Neurology, Graduate School of Medical Sciences, Fukuoka, Japan.
  • Kishida S; Hakusuikai Hatsuishi Hospital, Chiba, Japan.
  • Yamamura T; National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.
  • Ohtsuka N; Biogen Japan, Chuo-ku, Tokyo, Japan.
  • Ling Y; Biogen Japan, Chuo-ku, Tokyo, Japan.
  • Torii S; Biogen Japan, Chuo-ku, Tokyo, Japan.
  • Lucas N; Biogen, Cambridge, MA, USA.
  • Kuesters G; Biogen, Cambridge, MA, USA.
  • Steiner D; Biogen, Cambridge, MA, USA.
  • Tibung JT; Biogen Japan, Chuo-ku, Tokyo, Japan.
Neurol Ther ; 6(1): 39-55, 2017 Jun.
Article de En | MEDLINE | ID: mdl-27921221
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Clinical_trials / Prognostic_studies Langue: En Journal: Neurol Ther Année: 2017 Type de document: Article Pays d'affiliation: Japon Pays de publication: Nouvelle-Zélande
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Clinical_trials / Prognostic_studies Langue: En Journal: Neurol Ther Année: 2017 Type de document: Article Pays d'affiliation: Japon Pays de publication: Nouvelle-Zélande